
Advanced endoscopy fellow @WCM_GI via @UCSD_GI & @unlvmedicine
Joined November 2019
- Tweets207
- Following511
- Followers393
- Likes2.1K
Pinned Tweet
Happy for the graduating IM residents and can’t wait to see their future accomplishments. I am grateful to @ucsdim for the Top Fellow award. It was an honor to work with an outstanding group of residents!
#GITwitter
Nabil Noureddin retweeted
Join us on Friday, April 10, 2026 for 'ALD-ALLY 2026' - a virtual and in-person conference with 7.25 ACCME Credits - Alcohol-associated Liver Disease patients deserve ALcohol LiteracY
eventleaf.com/e/ALDALLY2026
#MedEd
Had the opportunity to present Grand Rounds on the evolving role of advanced endoscopy in GI oncology — from ESD to interventional EUS and how these techniques are reshaping management and patient care.
Grateful to the incredible advanced endoscopy mentors @WCM_GI, @drbobbybrown , and my amazing program director @ReemSharaiha for the mentorship, guidance, and support.
Thanks as well to our general GI fellows and staff who make this work possible.
Walking through the colon for #ColorectalCancerAwarenessMonth.
Colorectal cancer remains the 2nd leading cause of cancer death in the U.S., yet it is highly preventable with screening.
Colonoscopy and polyp detection save lives.
@ReemSharaiha @WCM_GI #DavidCarrLocke
@nyphospital @bsc_endoscopy
Nabil Noureddin retweeted
Several members of our team, including fellows, attended the #NYSGE Annual Dinner this week. They celebrated NYSGE's achievements and educational initiatives led by president @ReemSharaiha!
@FeliceSchnoll @katzpo @Michelle_Lee_MD @DrCriccoLizza @AdamBuckholz @WCMDeptofMed
Nabil Noureddin retweeted
A big congratulations to Dr. Tamas Gonda, newly appointed as President of the @NYSGE‼️Thank you also to @ReemSharaiha on her service & leadership as President over the past year.
We look forward to great things ahead in NY #gastroenterology & #endoscopy‼️ @MarkPochapin
Nabil Noureddin retweeted
Prof. Mazen Noureddin presents:
“Selecting therapy in MASH: matching drugs to phenotypes.”
Highlighting a practical, phenotype-driven framework tailoring treatment to metabolic profile, fibrosis risk, and comorbidities.
#BestofTLM #SASLT #AASLD #MASH
Nabil Noureddin retweeted
Artículo de Revisión
Ensayos clínicos en MASH y la cartera de medicamentos: un inminente tsunami
Noureddin
#LiverX
shorturl.at/oir5U
Nabil Noureddin retweeted
Drs Patrick T. Magahis and SriHari Mahadev discuss “Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." youtu.be/cFEn4tbjCuI
#GITwitter
@PatrickMagahis @ReemSharaiha @MarkHanscomMD
A powerful Presidential Address by NYSGE President @ReemSharaiha at the @nysge Annual Meeting — past lessons, present innovation, and the future of endoscopy.
@WCM_GI
Highly anticipated NYSGE Annual Course—an exceptional program led by NYSGE President and Director of Endoscopy @ReemSharaiha, with an outstanding faculty.
@WCM_GI @NYSGE
Please join us for the NYSGE Annual Course! Pertinent didactics, hands-on endoscopy training and incredible live cases! @NYSGE @ReemSharaiha @NikhilKumtaMD @laurenkhanna @shandrawes @EndoscopyOA @MouenKhashab @DrBloodandGuts
Nabil Noureddin retweeted
Prof. David Carr-Locke invites you to the 33rd @CedarsSinai International Endoscopy Symposium and Future of Endoscopy Meeting Jan 28–31, 2026.
A legacy meeting shaping the future of endoscopy. Open to all cedars.cloud-cme.com/endosco…
Nabil Noureddin retweeted
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - @TheLancet #livertwitter – at Hunters Creek Village, TX
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - The Lancet thelancet.com/journals/lance…
Nabil Noureddin retweeted
50 yrs of endoscopy wisdom - Carr-Locke
▪️Do best for patients
▪️Make every scope your best
▪️Keep growing
▪️Keep publishing
▪️Support fellows
▪️Value nurses & techs
▪️Happy home = job
▪️Happy job = home
▪️Partnerships matter
▪️Don’t take too serious
🎥 vumedi.com/video/50-years-of…
Nabil Noureddin retweeted
The 2️⃣0️⃣2️⃣5️⃣ advanced endoscopy 🥼fellows coming 💫 together to🍎 learn from this ✨stellar faculty about 🩻 ERCP and 💎cholangioscopy. Thank you @bostonsci ‼️@ASGEendoscopy #Gastroenterology #womeningi
Nabil Noureddin retweeted
Local Post-Procedural Cryoprevention Significantly Reduces the Incidence of Post-ERCP Pancreatitis
Azuma, et al.
📕 doi.org/10.14309/ajg.0000000…
@MLongMD @JasmohanBajaj
Nabil Noureddin retweeted
You are really leading this field, @NoureddinMD.
Truly awesome
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet thelancet.com/journals/lance…
Huge step forward for MASH patients — and for the hepatology field!
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet thelancet.com/journals/lance…
9
541
A breakthrough study for our MASH patients! @NoureddinMD
SYMMETRY trial: Efruxifermin was previously shown to reduce fibrosis in patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis. Research findings in patients with compensated cirrhosis are summarized in a new Quick Take video. nej.md/44vzhCN
11
708
Nabil Noureddin retweeted
SYMMETRY trial: Efruxifermin was previously shown to reduce fibrosis in patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis. Research findings in patients with compensated cirrhosis are summarized in a new Quick Take video. nej.md/44vzhCN







































